High doses of gonadotrophin-releasing hormone antagonist in in-vitro fertilization cycles do not adversely affect the outcome of subsequent freeze-thaw cycles.

@article{Kol1999HighDO,
  title={High doses of gonadotrophin-releasing hormone antagonist in in-vitro fertilization cycles do not adversely affect the outcome of subsequent freeze-thaw cycles.},
  author={S Kol and Avraham Lightman and T Hillensj{\'o} and Paul Devroey and B C Fauser and Basil Tarlatzis and B Mannaerts and Joseph Itskovitz-Eldor},
  journal={Human reproduction},
  year={1999},
  volume={14 9},
  pages={2242-4}
}
The clinical application of gonadotrophin-releasing hormone (GnRH) antagonists instead of GnRH agonists, to prevent spontaneous premature luteinizing hormone surge during ovarian stimulation for assisted reproduction treatment has been advocated. A recent, double-blind, dose-finding study, including six dosages of the GnRH antagonist ganirelix, in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (FSH), has indicated that high doses of GnRH antagonist (1 or 2 mg… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 18 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 10 references

Cryopreservation : the practicalities of evaluation

  • L. R. Nelson, V. Y. Fujimoto, R. B. Jaffe, S. E. Monroe
  • Hum . Reprod .
  • 1997

A prospective, randomized, assessor-blind multicentre study comparing recombinant and urinary follicle-stimulating hormone (Puregon versus Metrodin) in in-vitro fertilization

  • H. J. Out, B. M. Mannaerts, Driessen, S.G.A.J, H. J. Coelingh Bennink
  • Hum . Reprod .
  • 1995
1 Excerpt

Similar Papers

Loading similar papers…